ATE517629T1 - Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems - Google Patents
Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystemsInfo
- Publication number
- ATE517629T1 ATE517629T1 AT02774915T AT02774915T ATE517629T1 AT E517629 T1 ATE517629 T1 AT E517629T1 AT 02774915 T AT02774915 T AT 02774915T AT 02774915 T AT02774915 T AT 02774915T AT E517629 T1 ATE517629 T1 AT E517629T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- immune system
- crmp
- sequence
- system diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0111627A FR2829392B1 (fr) | 2001-09-07 | 2001-09-07 | Utilisation de crmps pour la fabrication d'un medicament destine a traiter les maladies liees a un dysfonctionnement du systeme immunitaire |
FR0113342A FR2830762B1 (fr) | 2001-10-16 | 2001-10-16 | Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire |
PCT/FR2002/003056 WO2003022298A2 (fr) | 2001-09-07 | 2002-09-09 | Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE517629T1 true ATE517629T1 (de) | 2011-08-15 |
Family
ID=26213178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02774915T ATE517629T1 (de) | 2001-09-07 | 2002-09-09 | Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems |
Country Status (7)
Country | Link |
---|---|
US (1) | US7820375B2 (de) |
EP (1) | EP1435993B1 (de) |
JP (1) | JP4499414B2 (de) |
AT (1) | ATE517629T1 (de) |
AU (1) | AU2002341090A1 (de) |
CA (1) | CA2461692A1 (de) |
WO (1) | WO2003022298A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2853909A1 (fr) * | 2003-04-16 | 2004-10-22 | Galderma Res & Dev | Genes du psoriasis |
US7935349B2 (en) * | 2006-03-17 | 2011-05-03 | The Royal Institution For The Advancement Of Learning/Mcgill University | CRMP4b inhibitory peptide |
EP1873527A1 (de) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Verfahren zur Identifizierung von CRMP-Modulatoren |
CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
DE102007022670A1 (de) * | 2007-05-11 | 2008-11-13 | Carsten Dr. Korth | Verwendung von CRMP1 als Target für chronisch psychiatrische Erkrankungen |
DE102007022669A1 (de) * | 2007-05-11 | 2008-11-20 | Carsten Dr. Korth | Verwendung von CRMP1 als Marker für chronisch psychiatrische Erkrankungen |
CA2785431A1 (en) * | 2009-07-16 | 2011-01-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cleaved and phosphorylated crmp2 as blood marker of inflammatory diseases of the central nervous system |
WO2011034864A1 (en) * | 2009-09-16 | 2011-03-24 | Life Technologies Corporation | Lysis buffers for extracting nucleic acids |
WO2014139539A1 (en) * | 2013-03-15 | 2014-09-18 | Syddansk Universitet | Inhibitor of dpysl3/crmp4 for treatment of bone loss |
ES2964981T3 (es) * | 2015-06-26 | 2024-04-10 | Univ California | Péptidos antigénicos y usos de los mismos para diagnosticar y tratar el autismo |
CN113238045B (zh) * | 2021-04-27 | 2021-12-28 | 南方医科大学南方医院 | Crmp2及抗crmp2抗体的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758337B1 (fr) * | 1997-01-14 | 1999-03-05 | Commissariat Energie Atomique | Methode de criblage de substances a action therapeutique dans le traitement des esst comprenant une etape d'isolement de la prpres, a partir de la rate, procede d'isolement de le prpres et ses applications |
FR2759701B1 (fr) * | 1997-02-19 | 1999-06-04 | Inst Nat Sante Rech Med | Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques |
FR2805540B1 (fr) * | 2000-02-29 | 2004-04-09 | Inst Nat Sante Rech Med | Nouvelle proteine ulip humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques |
US20020119944A1 (en) * | 2000-11-09 | 2002-08-29 | Michelle Aguera | Use of Ulip-and/or Ulip2 in the treatment of myelin disorders |
ZA200204907B (en) * | 2001-06-26 | 2003-03-03 | Univ Nat Taiwan | Collapsin Response Mediator Protein-1. |
-
2002
- 2002-09-09 EP EP02774915A patent/EP1435993B1/de not_active Expired - Lifetime
- 2002-09-09 JP JP2003526426A patent/JP4499414B2/ja not_active Expired - Fee Related
- 2002-09-09 CA CA002461692A patent/CA2461692A1/fr not_active Abandoned
- 2002-09-09 AT AT02774915T patent/ATE517629T1/de not_active IP Right Cessation
- 2002-09-09 US US10/488,554 patent/US7820375B2/en not_active Expired - Fee Related
- 2002-09-09 AU AU2002341090A patent/AU2002341090A1/en not_active Abandoned
- 2002-09-09 WO PCT/FR2002/003056 patent/WO2003022298A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20050106143A1 (en) | 2005-05-19 |
EP1435993B1 (de) | 2011-07-27 |
EP1435993A2 (de) | 2004-07-14 |
AU2002341090A1 (en) | 2003-03-24 |
JP2005508315A (ja) | 2005-03-31 |
CA2461692A1 (fr) | 2003-03-20 |
JP4499414B2 (ja) | 2010-07-07 |
WO2003022298A2 (fr) | 2003-03-20 |
WO2003022298A3 (fr) | 2004-05-06 |
US7820375B2 (en) | 2010-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Siracusano et al. | Host‐parasite relationship in cystic echinococcosis: an evolving story | |
Kaser et al. | The AVIT protein family: Secreted cysteine‐rich vertebrate proteins with diverse functions | |
EA200501891A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
ATE135371T1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
DE60129799D1 (de) | Verfahren zur steigerung des haarwuchses durch wnt polypeptid | |
EA200602015A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
HUP0202532A2 (hu) | Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása | |
ATE548388T1 (de) | An den interleukin-4-rezeptor bindende antikörper | |
ATE492563T1 (de) | Vollständige humane monoklonale antikörper gegen il-13 | |
EP1361229A3 (de) | Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper | |
NO20063026L (no) | Antistoffer | |
ATE517629T1 (de) | Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems | |
ATE380867T1 (de) | Lactoferrinrezeptorgen von moraxella | |
PT1214600E (pt) | Determinacao de proteinas de ligacao a adrenomedulina | |
ATE389416T1 (de) | Behandlung von knorpelerkrankungen | |
DK0948604T3 (da) | Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet | |
ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
ATE432287T1 (de) | Peptidfragmente mit den zelltod verhindernder aktivität | |
NO962596L (no) | Nytt tumorsupressorgen | |
DE50015355D1 (de) | Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz | |
WO2004047758A3 (en) | Methods of therapy and diagnosis using targeting of cells that express p2y10 | |
ATE512983T1 (de) | Rezeptor für das tgr3-like protein | |
WO2002021138A3 (de) | Die m30-genfamilie und ihre verwendung | |
DE69133067T2 (de) | Menschliche cyclin-a-zusammensetzungen, verfahren zu ihrer herstellung, nukleotidsequenz, verfahren und wirkstoffe zur bestimmung oder diagnose von zellvermehrung, verfahren und wirkstoffe zur hemmung der zellvermehrung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |